glp-1 roche obesity drug helps patients shed 22.7% of weight in mid-stage trial Roche's Obesity Pill Candidate Hit

This convergence of rising demand, regulatory scrutiny, and manufacturing ambition is reshaping Indias pharmaceutical landscape, particularly in the high-growth segment of GLP-1 receptor agonists (GLP1-RAs)

No single peptide dominates the literature research is split across four categories by mechanism: incretin-pathway compounds like GLP-3 RT, fragment-based lipolytic peptides like AOD-9604, growth-hormone-releasing analogs like Tesamorelin, and secretagogue pairings like CJC-1295/Ipamorelin

Market Competition and M&A The obesity markets deal-making frenzy shows no signs of slowing

Minutes 15-50: The Active Cooking Phase This is where everything happens at once